Reactions to serum eye drops-New Zealand experience and review of the literature.

IF 1.5 4区医学 Q3 HEMATOLOGY

Transfusion Medicine Pub Date : 2024-02-01 Epub Date: 2023-11-10 DOI:10.1111/tme.13017

Krishna G Badami, Malcolm McKellar

{"title":"Reactions to serum eye drops-New Zealand experience and review of the literature.","authors":"Krishna G Badami, Malcolm McKellar","doi":"10.1111/tme.13017","DOIUrl":null,"url":null,"abstract":"Background: Serum eye drops (SED) are used to treat ocular surface disease. Reactions to SED are poorly documented.Methods: We present our experience of self-reported reactions in New Zealand to SED (25%; autologous, allogeneic, or both) between 2003 and 2023, and a focused review of the literature.Results: In total, 1067 patients received SED treatment (562 autologous, 318 allogeneic, and 187 both). Three (0.5% of those treated with allogeneic SED) reported reactions. All appeared to be allergic. All were associated with allogeneic SED. We have information on two patients: one had an eye reaction; in the other, the gastrointestinal tract was involved. The literature contains few reports of reactions to SED. They have involved both autologous and allogeneic SED, and various SED concentrations. None appears to have been severe. Notably, no eye or systemic infections have been reported.Conclusions: Information on the types and frequencies of reactions to SED is poor. This may be due to: serum being less likely to cause reactions; eyes being resistant to reactions; reactions being rare, and insufficient use of SED having occurred; under-reporting related to SED use at home and reactions being mild. More robust monitoring for reactions to SED is needed.","PeriodicalId":23306,"journal":{"name":"Transfusion Medicine","volume":" ","pages":"61-65"},"PeriodicalIF":1.5000,"publicationDate":"2024-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Transfusion Medicine","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1111/tme.13017","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2023/11/10 0:00:00","PubModel":"Epub","JCR":"Q3","JCRName":"HEMATOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Background: Serum eye drops (SED) are used to treat ocular surface disease. Reactions to SED are poorly documented.

Methods: We present our experience of self-reported reactions in New Zealand to SED (25%; autologous, allogeneic, or both) between 2003 and 2023, and a focused review of the literature.

Results: In total, 1067 patients received SED treatment (562 autologous, 318 allogeneic, and 187 both). Three (0.5% of those treated with allogeneic SED) reported reactions. All appeared to be allergic. All were associated with allogeneic SED. We have information on two patients: one had an eye reaction; in the other, the gastrointestinal tract was involved. The literature contains few reports of reactions to SED. They have involved both autologous and allogeneic SED, and various SED concentrations. None appears to have been severe. Notably, no eye or systemic infections have been reported.

Conclusions: Information on the types and frequencies of reactions to SED is poor. This may be due to: serum being less likely to cause reactions; eyes being resistant to reactions; reactions being rare, and insufficient use of SED having occurred; under-reporting related to SED use at home and reactions being mild. More robust monitoring for reactions to SED is needed.

查看原文本刊更多论文

对血清滴眼液的反应新西兰的经验和文献综述。

背景：血清滴眼液用于治疗眼表疾病。对SED的反应记录不足。方法：我们介绍了2003年至2023年间新西兰对SED的自我报告反应（25%；自体、同种异体或两者兼有）的经验，并对文献进行了重点回顾。结果：总共有1067名患者接受了SED治疗（562名自体，318名异基因，187名同时接受）。三例（0.5%接受异基因SED治疗的患者）报告了反应。所有人似乎都过敏。均与异基因SED相关。我们有关于两名患者的信息：一名患者有眼部反应；另一种涉及胃肠道。文献中很少有关于SED反应的报道。它们涉及自体和同种异体SED，以及各种SED浓度。似乎没有一例病情严重。值得注意的是，没有眼部或全身感染的报告。结论：关于SED反应的类型和频率的信息很少。这可能是由于：血清不太可能引起反应；眼睛对反应有抵抗力；反应很少并且SED的使用不足；与在家使用SED有关的报道不足，反应轻微。需要对SED的反应进行更有力的监测。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Transfusion Medicine 医学-血液学

CiteScore

2.70

自引率

0.00%

发文量

审稿时长

6-12 weeks

期刊介绍： Transfusion Medicine publishes articles on transfusion medicine in its widest context, including blood transfusion practice (blood procurement, pharmaceutical, clinical, scientific, computing and documentary aspects), immunohaematology, immunogenetics, histocompatibility, medico-legal applications, and related molecular biology and biotechnology. In addition to original articles, which may include brief communications and case reports, the journal contains a regular educational section (based on invited reviews and state-of-the-art reports), technical section (including quality assurance and current practice guidelines), leading articles, letters to the editor, occasional historical articles and signed book reviews. Some lectures from Society meetings that are likely to be of general interest to readers of the Journal may be published at the discretion of the Editor and subject to the availability of space in the Journal.